Finance

Lists
600535:SHA
Tasly Pharmaceutical Group Co Ltd
CN¥13.82
+1.54%
(+0.21) 1D
Oct 30, 3:00:01 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600535...
Open
CN¥13.50
High
CN¥13.95
Low
CN¥13.50
Mkt. cap
20.65B
Avg. vol.
12.22M
Volume
13.32M
Dividend
2.46%
Quarterly dividend
CN¥0.09
Ex-dividend date
Oct 15, 2026
P/E ratio
16.88
52-wk high
CN¥16.24
52-wk low
CN¥12.90
EPS
CN¥0.82
Shares outstanding
1.51B
No. of employees
11K
Open
CN¥13.50
High
CN¥13.95
Low
CN¥13.50
Mkt. cap
20.65B
Avg. vol.
12.22M
Volume
13.32M
Dividend
2.46%
Quarterly dividend
CN¥0.09
Ex-dividend date
Oct 15, 2026
P/E ratio
16.88
52-wk high
CN¥16.24
52-wk low
CN¥12.90
EPS
CN¥0.82
Shares outstanding
1.51B
No. of employees
11K
News stories
From web sources and news partners
Profile
Tasly is a Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange. In 2009, Chinese pharmacologist Li Lianda claimed that a key product made by Tasly was unsafe. Tasly sued Li in 2013, alleging that Li's claim was baseless and was motivated by his financial and employment relations with Guangzhou Pharmaceutical, a direct competitor of Tasly. In September 2014, the Tianjin High People's Court ruled in favour of Tasly and ordered Li to issue an apology and pay Tasly 300,000 yuan in compensation. In February 2017, Tasly announced plans to form a joint venture with American multi-level marketing company Herbalife. Wikipedia
About Tasly Pharmaceutical Group Co Ltd
CEO-
Employees10.6K
Founded1994
Headquarters-
SectorPharmaceutical industry
Websitetasly.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.93B
2.16B
2.04B
1.87B
Cost of goods sold
659.71M
623.69M
654.28M
635.32M
Cost of revenue
659.71M
623.69M
654.28M
635.32M
Research and development expenses
132.23M
191.62M
102.48M
133.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
787.37M
874.15M
656.33M
696.27M
Operating expense
979.15M
1.08B
801.23M
841.61M
Total operating expenses
1.64B
1.70B
1.46B
1.48B
Operating income
286.94M
462.71M
580.75M
395.67M
Other non operating income
-6.11M
-733.75K
-232.24K
694.14K
EBT including unusual items
192.46M
461.52M
584.82M
224.72M
EBT excluding unusual items
289.16M
472.69M
588.33M
401.47M
Income tax expense
123.68M
96.97M
64.84M
22.24M
Effective tax rate
64.26%
21.01%
11.09%
9.90%
Other operating expenses
53.20M
17.23M
42.82M
-2.20M
Net income
120.59M
370.24M
522.44M
209.89M
Net profit margin
6.26%
17.10%
25.66%
11.21%
Earnings per share
-
-
-
-
Interest and investment income
14.84M
14.04M
11.58M
7.25M
Interest expense
-5.44M
-3.33M
-5.30M
-625.28K
Net interest expenses
9.39M
10.71M
6.29M
6.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
380.23M
555.99M
663.57M
488.96M
Gain or loss from assets sale
-8.61M
-
-409.04K
409.04K
Upcoming events
AI content may include mistakes. Learn more
Google apps